arthritis, psoriatic

Identification of the first signs or symptoms in different spondyloarthritis subtypes and their association with HLA-B27: data from REGISPONSER and RESPONDIA registries
María Ángeles Puche-Larrubia, Lourdes Ladehesa-Pineda, Janitzia Vázquez-Mellado, Alejandro Escudero-Contreras, Jordi Gratacós, Xavier Juanola, Eduardo Collantes-Estévez, Pilar Font-Ugalde, Clementina López-Medina

RMD Open Sep 2023, 9 (3) e003235; DOI: 10.1136/rmdopen-2023-003235
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
Michaela Koehm, Frank Behrens

RMD Open Sep 2023, 9 (3) e003166; DOI: 10.1136/rmdopen-2023-003166
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
Melanie Aureal, Milene Seauve, Soline Laplane, Jean-Christophe Lega, Natalia Cabrera, Fabienne Coury

RMD Open Sep 2023, 9 (3) e003064; DOI: 10.1136/rmdopen-2023-003064
Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study
Ying Ying Leung, Lihi Eder, Ana-Maria Orbai, Laura C Coates, Maarten de Wit, Josef S Smolen, Uta Kiltz, Penélope Palominos, Juan D Canete, Rossana Scrivo, Andra Balanescu, Emanuelle Dernis, Sandra Meisalu, Martin Soubrier, Umut Kalyoncu, Laure Gossec

RMD Open Sep 2023, 9 (3) e003157; DOI: 10.1136/rmdopen-2023-003157
Fatigue in patients with rheumatic and musculoskeletal diseases: a scoping review on definitions, measurement instruments, determinants, consequences and interventions
Esther Beckers, Kasper Hermans, Astrid Van Tubergen, Annelies Boonen

RMD Open Aug 2023, 9 (3) e003056; DOI: 10.1136/rmdopen-2023-003056
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
Xenofon Baraliakos, Effie Pournara, Laure Gossec, Philip J Mease, Roisin White, Eamonn O’Brien, Barbara Schulz, Helena Marzo-Ortega, Laura C Coates

RMD Open Jul 2022, 8 (2) e002303; DOI: 10.1136/rmdopen-2022-002303
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
Charlotte Krieckaert, Borja Hernández-Breijo, Johanna Elin Gehin, Guillaume le Mélédo, Alejandro Balsa, Meghna Jani, Denis Mulleman, Victoria Navarro-Compan, Gertjan Wolbink, John D Isaacs, Astrid van Tubergen

RMD Open Jun 2022, 8 (2) e002216; DOI: 10.1136/rmdopen-2022-002216
Free educational material on the EULAR school of rheumatology website
Christopher J Edwards

RMD Open Nov 2022, 8 (2) e002765; DOI: 10.1136/rmdopen-2022-002765
Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
Rene Lindholm Cordtz, Johan Askling, Benedicte Delcoigne, Karin E Smedby, Eva Baecklund, Christine Ballegaard, Pia Isomäki, Kalle Aaltonen, Bjorn Gudbjornsson, Thorvardur Jon Love, Sella Aarrestad Provan, Brigitte Michelsen, Joseph Sexton, Lene Dreyer, Karin Hellgren

RMD Open Dec 2022, 8 (2) e002776; DOI: 10.1136/rmdopen-2022-002776
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, Byron Padilla, Zailong Wang, Ann Eldred, Kurt de Vlam, Alan Kivitz

RMD Open Jun 2022, 8 (2) e002286; DOI: 10.1136/rmdopen-2022-002286

Main menu

arthritis, psoriatic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

arthritis, psoriatic

Pages